Today’s value-based reimbursement programs require hospitals and health systems to shorten the length of time patients are hospitalized, reduce readmissions and improve quality of care. When post-acute infusion therapy is required, these challenges can be heightened, but are readily achievable for individuals who are relatively healthy, stable and financially secure. However, the risk of poor outcomes increases significantly for those who: are sicker and have comorbidities; have limited caregiver support; lack transportation options; or have Medicare without a Medigap plan, a high-deductible commercial plan or are uninsured or underinsured.
Ensuring all patients can be successfully transitioned to post-acute care as soon as possible requires a forward-thinking infusion provider that can offer comprehensive solutions for all patient types. Option Care’s highly trained and experienced multi-disciplinary teams of Clinical Care Transition Specialists, infusion nurses, pharmacists, dietitians, patient registration and reimbursement professionals ensure any patient that is able to go home, can go home by offering the following support:
For example, Option Care worked with the family of one patient who needed therapy for complex medical issues, but ran out of hospital days covered by his insurance plan and couldn’t afford the copay for post-acute care. Rather than face thousands of dollars in out-of-pocket costs, Option Care helped arrange financial assistance allowing him to be discharged from the hospital and get his medicine at home.
Option Care also supports hospitals and health systems as a valued post-acute infusion partner with extensive payer coverage, demonstrated quality results and access to a wide range of limited distribution specialty infusion drugs that can be delivered in a more affordable setting.
Many patients require infusion treatment upon discharge from the hospital. Partnering with a quality infusion provider ensures effective care transitions for all individuals, mitigating the risk for hospitals and health systems and ensuring patients have access to the treatment they need.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen